ICAD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

35.00M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

86.00M

EV/OCF(TTM)

--

P/S(TTM)

5.00

iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.

Show More

Events Timeline

(ET)

2025-12-01

14:50:00

Deutsche Bank Lowers Icade Price Target to EUR 21, Maintains Hold Rating

2025-07-17 (ET)

2025-07-17

09:05:17

RadNet's DeepHealth complete acquisition of iCAD

2025-07-08 (ET)

2025-07-08

08:20:04

iCAD's proposed acquisition by RadNet recommended by ISS, Glass Lewis

2025-05-13 (ET)

2025-05-13

16:22:54

iCAD reports Q1 EPS (3c), consensus (6c)

2025-04-29 (ET)

2025-04-29

08:11:48

iCAD collaborates with Microsoft to provide access to mammography solutions

News

an image of Globenewswire

2025-06-15Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders

an image of Globenewswire

2025-06-15Globenewswire

HAPPY FATHER’S DAY and $HARHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger: SVT, SSBK, LNSR, iCAD

an image of Globenewswire

2025-06-09Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders

an image of PRnewswire

2025-06-09PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TTNP, LNSR, ICAD on Behalf of Shareholders

an image of Globenewswire

2025-06-09Globenewswire

$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to Act

an image of Globenewswire

2025-06-03Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ICAD, BSGM, SSBK on Behalf of Shareholders

3 Analyst Rating

Wall Street analysts forecast ICAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICAD is 3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

3 Hold

0 Sell

Hold

Current: 0.000

Low

3.00

Averages

3.25

High

3.50

Current: 0.000

Low

3.00

Averages

3.25

High

3.50

Kepler Cheuvreux

Hold

to

Reduce

downgrade

AI Analysis

2026-01-08

Reason

Kepler Cheuvreux

Price Target

AI Analysis

2026-01-08

downgrade

Hold

to

Reduce

Reason

Kepler Cheuvreux downgraded Icade to Reduce from Hold.

Laidlaw & Co.

Yale Jen

Strong Buy

to

Hold

Downgrades

n/a

2025-04-17

Reason

Laidlaw & Co.

Yale Jen

Price Target

n/a

2025-04-17

Downgrades

Strong Buy

to

Hold

Reason

Laidlaw analyst Yale Jen downgraded iCAD (ICAD) to Hold from Buy without a price target after the company announced it will be acquired by DeepHealth, a subsidiary of traded RadNet (RNDT). Although the valuation of the acquisition is "only modest," it offers iCAD investors a more immediate investment exit under the current more turbulent macro investment environment, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ICAD

Unlock Now

Valuation Metrics

The current forward P/E ratio for ICAD Inc (ICAD.O) is -9.50, compared to its 5-year average forward P/E of -17.74. For a more detailed relative valuation and DCF analysis to assess ICAD Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-17.74

Current PE

-9.50

Overvalued PE

5.16

Undervalued PE

-40.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

38.59

Current EV/EBITDA

-9.66

Overvalued EV/EBITDA

301.71

Undervalued EV/EBITDA

-224.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

3.90

Current PS

3.30

Overvalued PS

6.84

Undervalued PS

0.97

Financials

AI Analysis

Annual

Quarterly

Whales Holding ICAD

Trading Trends

People Also Watch

Frequently Asked Questions

What is ICAD Inc (ICAD) stock price today?

The current price of ICAD is 0 USD — it has increased 0 % in the last trading day.

What is ICAD Inc (ICAD)'s business?

iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a two-dimensional or three-dimensional mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting and algorithmically examining.

What is the price predicton of ICAD Stock?

Wall Street analysts forecast ICAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICAD is3.25 USD with a low forecast of 3.00 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ICAD Inc (ICAD)'s revenue for the last quarter?

ICAD Inc revenue for the last quarter amounts to 5.00M USD, decreased -1.61 % YoY.

What is ICAD Inc (ICAD)'s earnings per share (EPS) for the last quarter?

ICAD Inc. EPS for the last quarter amounts to -0.03 USD, decreased -40.00 % YoY.

How many employees does ICAD Inc (ICAD). have?

ICAD Inc (ICAD) has 66 emplpoyees as of January 31 2026.

What is ICAD Inc (ICAD) market cap?

Today ICAD has the market capitalization of 35.00M USD.